- Home
- RDAC vs IKNA Comparison
RDAC vs IKNA Comparison
Compare RDAC & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDAC
- IKNA
- Stock Information
- Founded
- RDAC 2024
- IKNA 2016
- Country
- RDAC China
- IKNA United States
- Employees
- RDAC N/A
- IKNA N/A
- Industry
- RDAC
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- RDAC
- IKNA Health Care
- Exchange
- RDAC NYSE
- IKNA Nasdaq
- Market Cap
- RDAC 75.2M
- IKNA 81.6M
- IPO Year
- RDAC 2024
- IKNA 2021
- Fundamental
- Price
- RDAC $10.06
- IKNA $1.42
- Analyst Decision
- RDAC
- IKNA Buy
- Analyst Count
- RDAC 0
- IKNA 2
- Target Price
- RDAC N/A
- IKNA $3.00
- AVG Volume (30 Days)
- RDAC 473.0
- IKNA 134.5K
- Earning Date
- RDAC 01-01-0001
- IKNA 03-11-2025
- Dividend Yield
- RDAC N/A
- IKNA N/A
- EPS Growth
- RDAC N/A
- IKNA N/A
- EPS
- RDAC N/A
- IKNA N/A
- Revenue
- RDAC N/A
- IKNA $659,000.00
- Revenue This Year
- RDAC N/A
- IKNA N/A
- Revenue Next Year
- RDAC N/A
- IKNA N/A
- P/E Ratio
- RDAC N/A
- IKNA N/A
- Revenue Growth
- RDAC N/A
- IKNA N/A
- 52 Week Low
- RDAC $9.98
- IKNA $1.22
- 52 Week High
- RDAC $10.41
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- RDAC N/A
- IKNA 36.12
- Support Level
- RDAC N/A
- IKNA $1.45
- Resistance Level
- RDAC N/A
- IKNA $1.53
- Average True Range (ATR)
- RDAC 0.00
- IKNA 0.06
- MACD
- RDAC 0.00
- IKNA -0.00
- Stochastic Oscillator
- RDAC 0.00
- IKNA 23.53
About RDAC RISING DRAGON ACQUISITION CORP
Rising Dragon Acquisition Corp is a blank check company.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.